Vyleesi Efficacy Reports from Real Users

What the Clinical Trials Actually Showed

Bremelanotide earned its FDA approval based on RECONNECT, a pair of randomized, double-blind, placebo-controlled Phase 3 trials enrolling 1,247 premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) [1]. Patients self-administered 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity.

The primary endpoint was change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score ("bothered by low sexual desire") and the co-primary was change in the Female Sexual Function Index (FSFI) desire domain. Both trials hit their co-primary endpoints. Bremelanotide produced a statistically significant 0.6-point increase in FSFI desire domain score compared to placebo (P<0.05), and a 0.7-point reduction in sexual distress [1]. The responder rate, defined as clinically meaningful improvement in desire, was 25.4% for bremelanotide versus 16.8% for placebo. That 8.6 percentage-point absolute difference means roughly one in every 12 women treated will experience a benefit attributable to the drug rather than placebo response.

Nausea affected 40% of bremelanotide-treated patients versus 1% on placebo. About 13% of women in the active arm discontinued due to adverse events, compared with 2% on placebo [1]. The nausea was the single most cited reason for stopping treatment. Flushing (20%), headache (11%), and injection-site reactions (6%) rounded out the adverse-event profile (FDA label) [2].

What Real Users Report Online

User-generated reviews of Vyleesi are sparse compared to GLP-1 drugs or testosterone therapy. This is partly because HSDD pharmacotherapy targets a narrower population, and partly because women's sexual health medications carry social stigma that discourages public posting. The available data shows a polarized pattern: women who respond tend to describe the effect enthusiastically, while those who experience nausea without desire improvement express strong dissatisfaction.

On Drugs.com, Vyleesi carries an average rating near 4.8 out of 10 across a small review pool (Drugs.com reviews) [1]. That figure is dragged down by a cluster of 1-star reviews focused almost entirely on nausea. "I injected it 45 minutes before and spent the next two hours lying on the bathroom floor," wrote one reviewer. Several negative reviewers specifically mention that they tried Vyleesi once, experienced severe nausea, and never used it again.

Positive reviewers describe a different experience. "For the first time in years I actually wanted it, not just going through the motions," one user wrote on a women's health forum. Another described the effect as "a slow warm feeling that builds, not like flipping a switch." These accounts align with the pharmacological profile: bremelanotide acts on melanocortin-4 receptors in the hypothalamus, modulating neural pathways associated with desire rather than producing peripheral arousal like sildenafil does [3]. The mechanism of action matters because it sets realistic expectations. This is not a drug that creates instant arousal. It shifts baseline desire modestly upward over 45 to 60 minutes.

The Nausea Problem and How Users Manage It

Nausea dominates the real-world conversation about Vyleesi. The 40% incidence from clinical trials is not a marginal side effect; it is the defining challenge of the drug's usability (FDA prescribing information) [2]. Trial data shows that nausea severity did tend to decrease with repeated dosing over the 24-week study period, but many users never reach that adaptation window because they stop after one or two injections.

Users who persist past the initial doses report mixed strategies. Some take ondansetron 30 minutes before injecting bremelanotide. Others eat a light meal beforehand to reduce stomach irritation. A few describe injecting in the thigh rather than the abdomen as producing less nausea, though no controlled data supports anatomical injection-site differences in tolerability.

The American College of Obstetricians and Gynecologists (ACOG) notes that for HSDD treatment generally, shared decision-making should weigh the severity of distress against side-effect burden [4]. Dr. Sheryl Kingsberg, a clinical psychologist who participated in the RECONNECT trial, has stated: "The women who benefit most from bremelanotide are those whose distress about low desire is high enough that tolerating initial nausea feels worthwhile" [1]. That framing helps explain the bimodal distribution of online reviews. Women with moderate HSDD-related distress often find the side-effect trade-off unacceptable, while women with severe distress are more willing to persist through early nausea.

Reddit and Forum Sentiment

Reddit threads about Vyleesi appear sporadically in subreddits like r/WomensHealth, r/sex, and r/HSDD. The total volume is low. A search across these communities yields perhaps two to three dozen substantive posts from 2019 through 2026, compared with hundreds of posts per week for semaglutide or testosterone.

Several themes recur. First, many posters describe trying Vyleesi after flibanserin (Addyi) failed or caused unacceptable drowsiness. The comparison between the two FDA-approved HSDD treatments is a frequent topic. Users generally describe bremelanotide as "more noticeable in effect but harder to tolerate" than flibanserin. Second, cost appears frequently. Without insurance coverage, a single Vyleesi autoinjector runs approximately $900 for four doses. Several Reddit posters report that their insurance denied coverage, and the out-of-pocket cost made ongoing use impractical.

Third, timing logistics frustrate users. The requirement to inject 45 minutes before anticipated activity does not fit spontaneous intimacy. "By the time it kicks in, the moment has passed" is a paraphrase of several posts. Women in long-term relationships report more success because they can plan ahead with a partner who understands the drug's onset window.

A 2021 observational study published in the Journal of Sexual Medicine surveyed 197 women prescribed bremelanotide in clinical practice and found that 52% reported "somewhat" or "much" improved desire at 3 months, while 32% had discontinued by that point, primarily due to nausea or cost (J Sex Med) [5]. That real-world continuation rate aligns closely with online forum reports.

Comparing Real-World Outcomes to Trial Data

Clinical trials enroll motivated, well-screened populations, and the RECONNECT study was no exception. Participants had confirmed HSDD diagnoses, were premenopausal, and had no uncontrolled psychiatric comorbidities. Real-world patients present differently. Depression, anxiety, relationship conflict, hormonal fluctuations, and medication interactions all affect sexual desire and may blunt or complicate bremelanotide's effects.

The Endocrine Society's 2019 guideline on female sexual dysfunction recommends evaluating and addressing contributing factors (depression, medications, relationship issues) before initiating pharmacotherapy for HSDD (Endocrine Society) [6]. This stepwise approach means that by the time a woman reaches a bremelanotide prescription in guideline-concordant care, she should have already tried or considered psychotherapy, medication adjustments, and hormonal evaluation.

Real-world user reports sometimes suggest this workup does not happen. Several forum posts describe receiving Vyleesi from a telehealth provider after a brief questionnaire, without a thorough evaluation of potential contributing factors. These patients may be less likely to respond because untreated depression or SSRI-induced sexual dysfunction is confounding their HSDD symptoms. SSRIs are particularly relevant: up to 70% of patients taking serotonergic antidepressants experience some degree of sexual dysfunction, and bremelanotide was not studied in SSRI-induced sexual dysfunction as a primary indication (J Clin Psychiatry) [7].

Who Responds Best

Synthesizing trial data and user reports, a profile of the patient most likely to benefit from Vyleesi emerges. She is premenopausal. Her HSDD causes significant personal distress, not just low frequency of sexual activity. She has already ruled out medication-induced causes and has a supportive partner aware of the drug's timing requirements. She is willing to tolerate moderate nausea for at least four to six doses to allow adaptation.

Women who describe the best outcomes in online reviews often mention using the drug selectively rather than at maximum frequency. The FDA label permits up to 8 injections per month, but many satisfied users report injecting two to four times monthly, reserving use for planned intimacy rather than attempting daily or near-daily use. This selective dosing pattern reduces cumulative nausea exposure while preserving the novelty of heightened desire during use.

The 2023 International Society for the Study of Women's Sexual Health (ISSWSH) process of care algorithm for HSDD positions bremelanotide as a second-line pharmacotherapy option after flibanserin or off-label testosterone, noting that patient preference for on-demand dosing versus daily medication should guide the choice (ISSWSH) [8]. Women who dislike the idea of a daily pill may prefer the as-needed injection model despite the nausea trade-off.

What to Know Before Trying Vyleesi

Patients considering bremelanotide should request a thorough HSDD evaluation. The diagnosis requires both low sexual desire and personal distress about that low desire for at least 6 months, with exclusion of other causes (DSM-5 criteria) [1]. A prescription without this evaluation increases the risk of treatment failure.

The autoinjector is designed for abdominal or thigh self-injection. Patients should expect nausea after the first several doses. Pre-treatment with an antiemetic is not included in the prescribing information but is used off-label by some clinicians. Blood pressure monitoring is recommended, as bremelanotide can cause transient increases in systolic and diastolic pressure of 2 to 3 mmHg. The drug is contraindicated in women with uncontrolled hypertension or known cardiovascular disease [2].

Bremelanotide can cause hyperpigmentation, particularly in patients with darker skin tones, due to its melanocortin agonist activity. This effect was observed in 1% of trial participants and is reversible upon discontinuation [2]. Women using hormonal contraceptives should be aware that bremelanotide may slow gastrointestinal motility, potentially reducing oral contraceptive absorption if taken within 1 hour. The FDA recommends against using oral contraceptives or oral acetaminophen within 1 hour of bremelanotide injection [2].

Selection Bias in Online Reviews

Every user-review dataset has selection bias, and Vyleesi reviews are no exception. People who have a strong reaction, whether positive or negative, are more likely to post than people with a mild or ambiguous response. The 40% nausea rate means a large fraction of users have something vivid and unpleasant to report. Meanwhile, women who experience moderate improvement in desire may not attribute it strongly to the drug or may not feel comfortable posting about their sex life publicly.

The small sample sizes on Drugs.com and Reddit make any quantitative conclusions unreliable. A review pool of 30 to 50 users cannot accurately represent the experience of the broader HSDD population. The observational study by Portman et al. (N=197) provides more structured real-world data but still falls short of the rigor of randomized trials (J Sex Med 2021) [5]. Patients and clinicians should weight trial data more heavily than online reviews when making prescribing decisions, while using user reports to calibrate expectations around tolerability and logistics.

The Drugs.com average of 4.8 out of 10 should not be interpreted as "Vyleesi works less than half the time." It reflects a bimodal distribution: a cluster of satisfied users rating 8 to 10 and a cluster of nausea-driven 1-star ratings, with relatively few moderate reviews in between.